Author Correction: CD98hc is a target for brain delivery of biotherapeutics
Kylie S. Chew(Denali Therapeutics (United States)), Mihalis S. Kariolis(Denali Therapeutics (United States)), Yinhan Zhou(Bristol-Myers Squibb (United States)), Robert G. Thorne(Denali Therapeutics (United States)), Gerald Maxwell Cherf(Denali Therapeutics (United States)), René Meisner(OncoMed (United States)), David Huynh(Denali Therapeutics (United States)), David Joy(Gladstone Institutes), Lakshman Annamalai(Denali Therapeutics (United States)), Y. Joy Yu Zuchero(Denali Therapeutics (United States)), Robert C. Wells(Denali Therapeutics (United States)), Diana Lac(Denali Therapeutics (United States)), Timothy Earr(Denali Therapeutics (United States)), Joseph McInnes(Texas Children's Hospital), Joseph Duque(Denali Therapeutics (United States)), Richard Daneman(University of California San Diego), Kendra J. Lechtenberg(Stanford Medicine), Johann Chow(Denali Therapeutics (United States)), Patricia Sacayon(Denali Therapeutics (United States)), Nicholas P. D. Liau(Denali Therapeutics (United States)), Hilda Solanoy, Mario Malfavon(University of California San Diego), Yaneth Robles‐Colmenares(University of California, San Francisco), Hai L. Tran(Denali Therapeutics (United States)), Amy Wing-Sze Leung(Denali Therapeutics (United States)), Kaja Bajc(University of California San Diego), Marie Blanchette(Université de Sherbrooke), Cathal Mahon(Denali Therapeutics (United States)), Michelle E. Pizzo(Denali Therapeutics (United States)), Joseph W. Lewcock(Denali Therapeutics (United States)), Padma Akkapeddi(Denali Therapeutics (United States)), Kapil Gadkar(Sea Turtle Conservancy), Hoang N. Nguyen(Denali Therapeutics (United States)), Ryan J. Watts(Denali Therapeutics (United States)), Katrina W. Lexa(Tetra Therapeutics (United States)), Arash Moshkforoush(Denali Therapeutics (United States)), Mark S. Dennis(Denali Therapeutics (United States)), Meredith Calvert(Temasek Life Sciences Laboratory), Darren Chan(University Health Network), Kaitlin Xa(Denali Therapeutics (United States)), Do Jin Kim(Denali Therapeutics (United States)), Raymond K. Tong, Alexander Yang(Denali Therapeutics (United States)), Mabel Tong(Denali Therapeutics (United States)), Audrey Gill(Epic Sciences (United States)), Kristen N. Knight(Denali Therapeutics (United States)), Devendra B. Srivastava(Denali Therapeutics (United States)), Elysia Roche(Denali Therapeutics (United States)), Edwin I. Lozano(Denali Therapeutics (United States)), Isabel Becerra(Denali Therapeutics (United States))
Cited by 2
Related Papers
The Blood–Brain Barrier
|Cold Spring Harbor Perspectives in Biology|2015|3.2k
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k
Engaging neuroscience to advance translational research in brain barrier biology
|Nature reviews. Neuroscience|2011|586
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
|Journal of Biological Chemistry|2002|496